Apogee Therapeutics, Inc.
APGE
$68.50
$1.732.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.61M | 17.10M | 17.46M | 16.71M | 15.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.06M | 71.28M | 73.17M | 63.10M | 75.88M |
| Operating Income | -78.06M | -71.28M | -73.17M | -63.10M | -75.88M |
| Income Before Tax | -69.33M | -64.96M | -66.02M | -55.26M | -67.20M |
| Income Tax Expenses | 62.00K | 61.00K | 72.00K | 83.00K | 18.00K |
| Earnings from Continuing Operations | -69.39M | -65.02M | -66.10M | -55.34M | -67.22M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.39M | -65.02M | -66.10M | -55.34M | -67.22M |
| EBIT | -78.06M | -71.28M | -73.17M | -63.10M | -75.88M |
| EBITDA | -77.65M | -70.87M | -72.77M | -62.89M | -75.81M |
| EPS Basic | -1.03 | -1.11 | -1.13 | -0.95 | -1.17 |
| Normalized Basic EPS | -0.64 | -0.69 | -0.71 | -0.59 | -0.73 |
| EPS Diluted | -1.03 | -1.11 | -1.13 | -0.95 | -1.17 |
| Normalized Diluted EPS | -0.64 | -0.69 | -0.71 | -0.59 | -0.73 |
| Average Basic Shares Outstanding | 67.36M | 58.77M | 58.43M | 58.20M | 57.25M |
| Average Diluted Shares Outstanding | 67.36M | 58.77M | 58.43M | 58.20M | 57.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |